MBX Biosciences (MBX) AGM 2026 summary
Event summary combining transcript, slides, and related documents.
AGM 2026 summary
4 Jun, 2026Opening remarks and agenda
Meeting called to order, minutes recorded by legal counsel, and agenda based on notice and proxy statement mailed to stockholders.
Directors and audit firm representatives introduced; meeting held in accordance with bylaws and Delaware law.
Stockholders entitled to vote as of April 10, 2026, with records available for inspection prior to the meeting.
Voting and question procedures explained, with Inspector of Elections appointed and polls opened at 8:03 A.M.
Board and executive committee updates
Two nominees, Patrick J. Heron and Edward T. Mathers, put forward for election as Class II directors to serve until 2029.
No stockholder nominations received; board unanimously recommends voting in favor.
Corporate governance
Audit committee, comprised entirely of independent directors, appointed Ernst & Young LLP as independent auditor for 2026.
Board submits auditor ratification to stockholders as a matter of good governance, though not required by bylaws.
Latest events from MBX Biosciences
- Once-weekly canvuparatide sustained efficacy and safety at one year, supporting Phase III advancement.MBX
Study result12 Jun 2026 - Advancing once-weekly and monthly therapies for obesity and hypoparathyroidism with key data ahead.MBX
Jefferies Global Healthcare Conference 20263 Jun 2026 - Once-monthly MBX 4291 achieved 7% weight loss and strong tolerability in phase I.MBX
Status update18 May 2026 - Audit Committee and board changes, plus new consulting agreement with equity awards.MBX
Proxy filing8 May 2026 - Q1 2026 net loss narrowed, $440M cash runway into 2029, and Phase 3 trial prep advanced.MBX
Q1 20267 May 2026 - Vote on two director elections and auditor ratification at the June 2026 virtual meeting.MBX
Proxy filing22 Apr 2026 - Virtual meeting to elect directors and ratify auditor, with robust governance and compliance.MBX
Proxy filing22 Apr 2026 - Advanced clinical pipeline and raised capital, supporting operations into 2029.MBX
Q4 202512 Mar 2026 - Phase III for once-weekly PTH therapy and monthly obesity treatments advance with key data in 2024.MBX
Barclays 28th Annual Global Healthcare Conference11 Mar 2026